APO-LEVOCARB 250 MG
LEVODOPA : 250 MG CARBIDOPA : 25 MG · DIN 02195968 · APOTEX INC
Health Canada status: MARKETED
What is APO-LEVOCARB?
APO-LEVOCARB 250 MG contains LEVODOPA : 250 MG CARBIDOPA : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02195968, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Aug-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-LEVOCARB used for?
Treatment of Parkinson's disease. Not recommended for drug-induced extrapyramidal reactions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02195968 |
|---|---|
| Brand name | APO-LEVOCARB |
| Generic / active ingredient | LEVODOPA : 250 MG CARBIDOPA : 25 MG |
| Manufacturer | APOTEX INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR |
| AHFS class | 28:36.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-Aug-2024 |
| Original market date | 1995-12-31 00:00:00 |
How is it administered?
Individualized titration. Start 100/25 mg TID. If switching from levodopa, discontinue levodopa for 12+ hours and start at 20% of previous dose. Swallow whole; do not chew, divide, or crush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard section 11 was in TOC but text cut off). Typical USP storage applies.
How is it supplied?
Bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity; nonselective MAOIs; uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary, or renal disease; narrow angle glaucoma; history of melanoma; sympathomimetics.
Warnings and precautions
Sudden onset of sleep; somnolence; dyskinesia; hallucinations; impulse control disorders; depression/suicidality; neuroleptic malignant syndrome if abruptly discontinued; melanoma risk.
What can be used instead?
Other Canadian products sharing ATC code N04BA02 LEVODOPA AND DECARBOXYLASE INHIBITOR. 23 of 44 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-LEVOCARB CR | 200 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02245211 |
| AA-LEVOCARB CR | 25 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02272873 |
| AG-LEVOCARB | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02551365 |
| APO-LEVOCARB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02195941 |
| APO-LEVOCARB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02195933 |
| AURO-LEVOCARB | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531593 |
| AURO-LEVOCARB | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531607 |
| AURO-LEVOCARB | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02531615 |
| DUODOPA | 5 MG | GEL | ABBVIE CORPORATION | MARKETED | DIN 02292165 |
| JAMP LEVOCARB | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02546396 |
Who else supplies LEVODOPA AND DECARBOXYLASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVODOPA AND DECARBOXYLASE INHIBITOR appears in 108 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.